NCT00686829View on ClinicalTrials.gov

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

October 21, 2010

Study Completion Date

October 21, 2010

Conditions
HIVHIV Infections
Interventions
DRUG

Vicriviroc maleate

VCV 30 mg tablet once daily by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00686829 - Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100) | Biotech Hunter | Biotech Hunter